Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Ofichem Acquires Swedish Site from Meribel Pharma Solutions | Contract Pharma

What are you searching for?

Sign in
Breaking News

Ofichem Acquires Swedish Site from Meribel Pharma Solutions

Enhances Ofichem’s innovation offering and expands its biotech footprint across Nordic countries.

Author Image

By: Charlie Sternberg

Associate Editor, Contract Pharma

Meribel Pharma Solutions’ site in Uppsala, Sweden.

Ofichem, a European CDMO specializing in high-quality active pharmaceutical ingredients (APIs) and integrated drug development and manufacturing services, has acquired Meribel Pharma Solutions’ site in Uppsala, Sweden, enhancing its ability to support early-phase, IP-driven drug substance development and expanding its non-GMP capabilities in the small-molecule space.

The Uppsala site, formerly part of Recipharm, is home to 20 employees and specializes in small-scale, early-phase development work. The expertise on offer at the facility spans traditional small molecule and emerging modalities such as antibody-drug conjugates (ADCs), oligonucleotides and proteolysis-targeting chimeras (PROTACs), expanding Ofichem’s non-GMP capabilities in early-stage development.

“This acquisition is a strategic building block in Ofichem’s broader transformation,” said Dr. Weite H. Oldenziel, CEO and owner of Ofichem. “Our goal is to serve innovative biotech companies with agile, early-stage development solutions, and this site offers precisely the expertise and technologies we need to deliver on that vision.”

The acquisition reflects Ofichem’s evolving focus, building on its foundation serving generics and mid-sized pharma to now invest more deeply in services for biotech innovators.

The site will operate in close coordination with Ofichem’s GMP manufacturing operations in Ter Apel, the Netherlands, creating a seamless path from early-stage research to commercial production. The acquisition also provides access to a portfolio of more than 40 biotech and mid-sized pharma clients, expanding Ofichem’s reach across the Nordic countries.

“We are proud to have found in Ofichem a reliable and respected partner who shares our values and unwavering focus on customer success,” said Bruce Vielle, CEO of Meribel. “This agreement is not only a positive step for both organizations but especially for the dedicated team and ongoing projects at the Uppsala site.

Looking ahead, Ofichem plans to further grow and expand its early-stage drug substance network, including evaluations of larger-scale GMP manufacturing sites in Europe and North America. Earlier this year, the company also agreed to acquire Aviva.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics